• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Teva Pharmaceutical Industries

Teva Pharmaceutical Industries

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Research
  1. Teva Announces Supreme Court Denial of Request for Interim Relief to Stay Court of Appeals Ruling for COPAXONE® Patent Due to the Potential for the Company to Recover Patent Infringement Damages

    Teva Announces Supreme Court Denial of Request for Interim Relief to Stay Court of Appeals Ruling for COPAXONE® Patent Due to the Potential for the Company to Recover Patent Infringement Damages

  2. Supreme Court Chief Justice Denies Teva's Request for an Injunction Relating to Generic Copaxone®; Clears Legal Hurdle for Mylan to Launch at Market Formation

    Supreme Court Chief Justice Denies Teva's Request for an Injunction Relating to Generic Copaxone®; Clears Legal Hurdle for Mylan to Launch at Market Formation

  3. Research and Markets: World Market for Biosimilars to 2017: EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others

    Research and Markets: World Market for Biosimilars to 2017: EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others

  4. Judge Upholds Validity of Eli Lilly Patent

    Judge Upholds Validity of Eli Lilly Patent

  5. Judge Upholds Validity of Eli Lilly Patent

    Judge Upholds Validity of Eli Lilly Patent

  6. United States PTO Rejects Teva's '808 Patent Reissue Application on Copaxone® for the Second Time

    United States PTO Rejects Teva's '808 Patent Reissue Application on Copaxone® for the Second Time

  7. Research and Markets: Distribution on the Pharmaceutical Market in Central Europe 2013: Comparative Analysis

    Research and Markets: Distribution on the Pharmaceutical Market in Central Europe 2013: Comparative Analysis

  8. ERYTECH adds a new product candidate to its tumor starvation development portfolio

    ERYTECH adds a new product candidate to its tumor starvation development portfolio

  9. ERYTECH Receives Orphan Drug Designation by the FDA for ERY-ASP in Acute Myeloid Leukemia

    ERYTECH Receives Orphan Drug Designation by the FDA for ERY-ASP in Acute Myeloid Leukemia

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.